en · de · es · pt
cjc-1295-notes.peptides3081.com › Data › Background And Receptor Mechanism — Questions and Answers

Background And Receptor Mechanism — Questions and Answers

By Editorial Desk · published 2026-05-18 · last reviewed 2026-06-11 · Data

A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-06-11 and is reviewed periodically as new material appears.

Background and Receptor Mechanism

Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.

At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.

Handling Storage and Quality Control

Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.

Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.

Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.

Cjc-1295 at a glance

PropertyValueNotes
Molecular weight, DAC formAbout 3647 DaVaries with salt form
Molecular weight, non-DAC formAbout 3358 DaMOD GRF(1-29)
Solubility classWater solubleAlso dissolves in polar solvents
Reported half-life, DAC formAbout five to eight daysValues from human studies
Common synonymsCJC-1295; MOD GRF(1-29)Name depends on variant

Molecular Background and Naming

Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

Related pages on this site

Background and Naming Conventions

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.

The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.

Notes from published material

=== Other === Other physical integration methods (spray or spin coating, blending, and vacuum filtration) have been developed for paper electronics, but have yet to be implemented in paper-based microfluidic devices.

=== Oxford debate walkout, 2013 === On 20 February 2013, Galloway walked out of a publicised debate when he found out that his opponent had Israeli citizenship. The debate, hosted by Oxford University's Christ Church, was on the topic "Israel should withdraw immediately from the West Bank". Galloway interrupted his opponent, Eylon Levy, a third-year PPE student, to ask whether he was an Israeli. When Levy acknowledged his joint British–Israeli nationality, Galloway stood up and stated "I don't recognise Israel and I don't debate with Israelis" and left the meeting. Explaining his actions on his Facebook page, Galloway wrote:

== Occurrence in food == HMF is practically absent in fresh food, but it is naturally generated in sugar-containing food during heat-treatments like drying or cooking. Along with many other flavor- and color-related substances, HMF is formed in the Maillard reaction as well as during caramelization. In these foods it is also slowly generated during storage. Acid conditions favour generation of HMF. HMF is a well known component of baked goods. Upon toasting bread, the amount increases from 14.8 (5 min.) to 2024.8 mg/kg (60 min). It is also formed during coffee roasting, with up to 769 mg/kg. It is a good wine storage time−temperature marker, especially in sweet wines such as Madeira and those sweetened with grape concentrate arrope.

=== Gene therapy === Researchers are working on a gene editing method to correct a mutation that leads to Duchenne muscular dystrophy (DMD). Researchers used a technique called CRISPR/Cas9-mediated genome editing, which can precisely remove a mutation in the dystrophin gene in DNA, allowing the body's DNA repair mechanisms to replace it with a normal copy of the gene. Genome editing through the CRISPR/Cas9 system is not currently feasible in humans. However, it may be possible, through advancements in technology, to use this technique to develop therapies for DMD in the future. In 2007, researchers did the world's first clinical (viral-mediated) gene therapy trial for Duchenne MD. Biostrophin is a delivery vector for gene therapy in the treatment of Duchenne muscular dystrophy and Becker muscular dystrophy.

July 11, 1975: Law on education (Haby Law); compulsory schooling applies to both boys and girls from ages 6 to 16, with no difference in education between them, and coeducation is required. July 11, 1975: Law amending and supplementing the Labor Code regarding special rules for women's work, as well as Article L298 of the Social Security Code and Articles 187-1 and 416 of the Penal Code. July 15, 1975: Legal authorization of divorce by mutual consent. December 31, 1979: Law permanently extending the provisions of the 1975 "Veil Law," while also removing some obstacles to access to abortion. April 29, 1976: Decree on the conditions of entry and stay in France for family members of foreigners authorized to reside in France. July 9, 1976: Law with various social protection measures for the family. September 21, 1976: Decree on the Delegate for Women's Status, replacing the Secretary of State for Women's Status. December 22, 1976: Law amending certain provisions on adoption. December 28, 1976: Decree on the organization of training in nursery and primary schools. July 12, 1977: Law establishing a family supplement replacing the single salary allowance, the stay-at-home mother's allowance, and the childcare allowance as of January 1, 1978. July 12, 1977: Law establishing parental education leave. November 10, 1977: Decree establishing a family supplement replacing the single salary allowance, the stay-at-home mother's allowance, and the childcare allowance as of January 1, 1978.

Sources: en.wikipedia.org

Background from the literature

Direct or tubed flaps involve having the flap connected to both the donor and recipient sites simultaneously, forming a bridge. This allows blood to be supplied by the donor site while a new blood supply from the recipient site is formed. Once this happens, the bridge can be disconnected from the donor site if necessary, completing the transfer. A free flap has the blood supply cut and then reattached microsurgically to a new blood supply at the recipient site.

The most common uses for enzyme inhibitors are as drugs to treat disease. Many of these inhibitors target a human enzyme and aim to correct a pathological condition. For instance, aspirin is a widely used drug that acts as a suicide inhibitor of the cyclooxygenase enzyme. This inhibition in turn suppresses the production of proinflammatory prostaglandins and thus aspirin may be used to reduce pain, fever, and inflammation. As of 2017, an estimated 29% of approved drugs are enzyme inhibitors of which approximately one-fifth are kinase inhibitors. A notable class of kinase drug targets is the receptor tyrosine kinases which are essential enzymes that regulate cell growth; their over-activation may result in cancer. Hence kinase inhibitors such as imatinib are frequently used to treat malignancies. Janus kinases are another notable example of drug enzyme targets. Inhibitors of Janus kinases block the production of inflammatory cytokines and hence these inhibitors are used to treat a variety of inflammatory diseases in including arthritis, asthma, and Crohn's disease. An example of the structural similarity of some inhibitors to the substrates of the enzymes they target is seen in the figure comparing the drug methotrexate to folic acid. Folic acid is the oxidised form of the substrate of dihydrofolate reductase, an enzyme that is potently inhibited by methotrexate. Methotrexate blocks the action of dihydrofolate reductase and thereby halts thymidine biosynthesis.

=== Erectile dysfunction === Smoking is a key cause of erectile dysfunction (ED). The incidence of erectile dysfunction (difficulty achieving and maintaining a penile erection) is approximately 85 percent higher in men who smoke compared to men who do not smoke. Smoking causes impotence because it promotes arterial narrowing and damages cells lining the inside of the arteries, thus leading to reduce penile blood flow.

When the fruit is ripe, it is almost always hand-picked, using either "selective picking", where only the ripe fruit is removed, or "strip-picking", where all of the fruit is removed from a limb all at once. Selective picking yields higher-quality coffee because the cherries are picked at their ripest. Indiscriminate strip-picking harvests unripe, ripe, and over-ripe fruit, requiring sorting after picking. Two methods are primarily used to process coffee berries. The first, "wet" or "washed" process, has historically usually been carried out in Central America and areas of Africa. The flesh of the cherries is separated from the seeds and then the seeds are fermented by soaking in water for about two days. This softens the mucilage, a sticky pulp residue attached to the seeds; it is then washed off with water. The "dry processing" method, cheaper and simpler, was historically used for lower-quality beans in Brazil and much of Africa, but now brings a premium when done well. Twigs and other foreign objects are separated from the berries, and the fruit is then spread out in the sun on concrete, bricks or raised beds for two to three weeks, turned regularly for even drying. In Asia, a third type of processing is occasionally used: the Asian palm civet eats coffee berries and excretes the beans. The civet chooses to harvest the ripest cherries; its digestive system then processes the beans by breaking down the mucilage and pulp surrounding the seed. Once the seeds are excreted by the civet, they can be harvested, processed and sold as a niche product.

Sources: en.wikipedia.org

Frequently asked questions

What is CJC-1295?

It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.

How do the DAC and non-DAC forms differ?

The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.

What receptor does it act on?

It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.

How should the lyophilized powder be stored?

The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.

Network